ANI Pharmaceuticals Analyst Ratings
ANI Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/19/2023 | 25.15% | Guggenheim | → $72 | Reiterates | Buy → Buy |
| 09/13/2023 | 25.15% | Guggenheim | → $72 | Reiterates | Buy → Buy |
| 08/22/2023 | 26.89% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 08/21/2023 | 21.68% | Truist Securities | → $70 | Reiterates | Buy → Buy |
| 08/10/2023 | 25.15% | Guggenheim | $62 → $72 | Maintains | Buy |
| 07/27/2023 | 7.77% | Guggenheim | $59 → $62 | Maintains | Buy |
| 07/21/2023 | 4.29% | Truist Securities | $52 → $60 | Maintains | Buy |
| 05/09/2023 | 2.56% | Guggenheim | $55 → $59 | Maintains | Buy |
| 05/09/2023 | -9.61% | Truist Securities | $50 → $52 | Maintains | Buy |
| 05/09/2023 | -14.83% | Raymond James | $48 → $49 | Maintains | Outperform |
| 05/09/2023 | 4.29% | HC Wainwright & Co. | $53 → $60 | Maintains | Buy |
| 03/13/2023 | -7.87% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
| 03/01/2023 | -4.4% | Guggenheim | → $55 | Initiates Coverage On | → Buy |
| 02/21/2023 | -13.09% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 09/07/2022 | -13.09% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 08/09/2022 | -16.57% | Raymond James | $47 → $48 | Maintains | Outperform |
| 03/16/2022 | -18.3% | Raymond James | $65 → $47 | Maintains | Outperform |
| 11/02/2021 | 12.98% | Raymond James | $60 → $65 | Maintains | Outperform |
| 11/02/2021 | 21.68% | Truist Securities | → $70 | Initiates Coverage On | → Buy |
| 05/10/2021 | 4.29% | Raymond James | $40 → $60 | Maintains | Outperform |
| 08/03/2020 | -30.47% | Raymond James | $49 → $40 | Maintains | Outperform |
| 05/08/2020 | -14.83% | Raymond James | $65 → $49 | Maintains | Outperform |
| 05/07/2020 | -30.47% | Cantor Fitzgerald | $78 → $40 | Downgrades | Overweight → Neutral |
| 04/30/2020 | 0.82% | Guggenheim | $62 → $58 | Maintains | Buy |
| 02/28/2020 | 12.98% | Raymond James | $75 → $65 | Maintains | Outperform |
| 11/07/2019 | 30.37% | Raymond James | $82 → $75 | Maintains | Outperform |
| 09/12/2019 | 32.1% | Guggenheim | → $76 | Initiates Coverage On | → Buy |
| 05/10/2019 | 42.53% | Raymond James | $73 → $82 | Downgrades | Strong Buy → Outperform |
| 11/12/2018 | 21.68% | Canaccord Genuity | $75 → $70 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月19日 | 25.15% | 古根海姆 | →$72 | 重申 | 購買→購買 |
| 09/13/2023 | 25.15% | 古根海姆 | →$72 | 重申 | 購買→購買 |
| 2023年08月22日 | 26.89% | HC Wainwright公司 | $60→$73 | 維護 | 買 |
| 2023年08月21日 | 21.68% | Truist證券 | →$70 | 重申 | 購買→購買 |
| 2023年08月10日 | 25.15% | 古根海姆 | $62→$72 | 維護 | 買 |
| 07/27/2023 | 7.77% | 古根海姆 | $59→$62 | 維護 | 買 |
| 07/21/2023 | 4.29% | Truist證券 | $52→$60 | 維護 | 買 |
| 05/09/2023 | 2.56% | 古根海姆 | $55→$59 | 維護 | 買 |
| 05/09/2023 | -9.61% | Truist證券 | $50→$52 | 維護 | 買 |
| 05/09/2023 | -14.83% | 雷蒙德·詹姆斯 | $48→$49 | 維護 | 跑贏大盤 |
| 05/09/2023 | 4.29% | HC Wainwright公司 | $53→$60 | 維護 | 買 |
| 03/13/2023 | -7.87% | HC Wainwright公司 | $50→$53 | 維護 | 買 |
| 03/01/2023 | -4.4% | 古根海姆 | →$55 | 開始承保 | →購買 |
| 02/21/2023 | -13.09% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 09/07/2022 | -13.09% | HC Wainwright公司 | →$50 | 開始承保 | →購買 |
| 08/09/2022 | -16.57% | 雷蒙德·詹姆斯 | $47→$48 | 維護 | 跑贏大盤 |
| 03/16/2022 | -18.3% | 雷蒙德·詹姆斯 | $65→$47 | 維護 | 跑贏大盤 |
| 11/02/2021 | 12.98% | 雷蒙德·詹姆斯 | $60→$65 | 維護 | 跑贏大盤 |
| 11/02/2021 | 21.68% | Truist證券 | →$70 | 開始承保 | →購買 |
| 2021/05/10 | 4.29% | 雷蒙德·詹姆斯 | $40→$60 | 維護 | 跑贏大盤 |
| 08/03/2020 | -30.47% | 雷蒙德·詹姆斯 | $49→$40 | 維護 | 跑贏大盤 |
| 05/08/2020 | -14.83% | 雷蒙德·詹姆斯 | $65→$49 | 維護 | 跑贏大盤 |
| 05/07/2020 | -30.47% | 康託·菲茨傑拉德 | $78→$40 | 評級下調 | 超重→中性 |
| 04/30/2020 | 0.82% | 古根海姆 | $62→$58 | 維護 | 買 |
| 02/28/2020 | 12.98% | 雷蒙德·詹姆斯 | $75→$65 | 維護 | 跑贏大盤 |
| 2019/07/11 | 30.37% | 雷蒙德·詹姆斯 | $82→$75 | 維護 | 跑贏大盤 |
| 2019/12/09 | 32.1% | 古根海姆 | →$76 | 開始承保 | →購買 |
| 2019年5月10日 | 42.53% | 雷蒙德·詹姆斯 | $73→$82 | 評級下調 | 強勢買入→跑贏大盤 |
| 2018年11月12日 | 21.68% | 卡納科特·格納奇 | $75→$70 | 維護 | 買 |
What is the target price for ANI Pharmaceuticals (ANIP)?
ANI製藥(ANIP)的目標價是多少？
The latest price target for ANI Pharmaceuticals (NASDAQ: ANIP) was reported by Guggenheim on October 19, 2023. The analyst firm set a price target for $72.00 expecting ANIP to rise to within 12 months (a possible 25.15% upside). 14 analyst firms have reported ratings in the last year.
古根海姆於2023年10月19日報道了ANI製藥(納斯達克：ANIP)的最新目標價。這家分析公司將目標價定為72.00美元，預計Anip將在12個月內上漲(可能上漲25.15%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
ANI製藥(ANIP)的最新分析師評級是多少？
The latest analyst rating for ANI Pharmaceuticals (NASDAQ: ANIP) was provided by Guggenheim, and ANI Pharmaceuticals reiterated their buy rating.
古根海姆提供了對ANI製藥(納斯達克代碼：ANIP)的最新分析師評級，ANI製藥重申了其買入評級。
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
ANI製藥(ANIP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on October 19, 2023 so you should expect the next rating to be made available sometime around October 19, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與ANI製藥的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ANI製藥的上一次評級是在2023年10月19日提交的，所以你應該預計下一次評級將在2024年10月19日左右的某個時候公佈。
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
分析師對ANI製藥(ANIP)的評級正確嗎？
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $0.00 to $72.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $57.53, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的ANI製藥(ANIP)評級被重申，目標價在0.00美元至72.00美元之間。ANI製藥(ANIP)目前的交易價格為57.53美元，在分析師的預測區間內。